Central Obesity, the Liver and Heart in the Psoriatic Patient
In this slideshow, we highlight a Brazilian study that examines the effects of biologics on the three most common psoriasis comorbidities: Metabolic syndrome, cardiovascular disease and fatty liver disease.
Psoriasis is associated with an extensive list of comorbidities ranging from erectile dysfunction to bronchial asthma. But there are three that are exponentially more common than others:Â Metabolic syndrome, cardiovascular disease and fatty liver disease. In this slideshow, we highlight a Brazilian study that examines the effects of treatment with infliximab, adalimumab, etanercept and ustekinumab in psoriasis patients with these three comorbidities.Â
References:
André Vicente Esteves de Carvalho, Ricardo Romiti, Cacilda da Silva Souza, et al. "Psoriasis comorbidities: complications and benefits of immunobiological treatment," Anais Brasileiros de Dermatologia. November/December 2016. http://dx.doi.org/10.1590/abd1806-4841.20165080
